Cassava Sciences Inc.

NASDAQ: SAVA · Real-Time Price · USD
2.12
-0.03 (-1.40%)
At close: Jun 05, 2025, 3:59 PM
2.12
0.16%
After-hours: Jun 05, 2025, 07:58 PM EDT

Company Description

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases.

Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019.

Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Cassava Sciences Inc.
Cassava Sciences Inc. logo
Country United States
IPO Date Jul 14, 2000
Industry Biotechnology
Sector Healthcare
Employees 30
CEO Richard Jon Barry

Contact Details

Address:
7801 North Capital of Texas Highway
Austin, Texas
United States
Website https://www.cassavasciences.com

Stock Details

Ticker Symbol SAVA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001069530
CUSIP Number 14817C107
ISIN Number US14817C1071
Employer ID 91-1911336
SIC Code 2834

Key Executives

Name Position
Richard Jon Barry Chief Executive Officer, President & Director
Eric J. Schoen Chief Financial Officer
Dr. Angélique Bordey Ph.D. Senior Vice President of Neuroscience
Dr. George Thornton Ph.D. Senior Vice President of Technology
Dr. Michael Marsman Pharm.D. Senior Vice President of Regulatory Affairs
Freda Nassif Chief Business Officer & Chief Commercial Officer
Jack Moore Ph.D. Senior Vice President of Clinical Development
Jaren Landen Chief Clinical Development Officer
Michael Zamloot Senior Vice President of Technical Operations
R. Christopher Cook J.D. Chief Operating & Legal Officer

Latest SEC Filings

Date Type Title
May 27, 2025 4 Filing
May 27, 2025 4 Filing
May 27, 2025 4 Filing
May 27, 2025 4 Filing
May 27, 2025 4 Filing
May 27, 2025 8-K Current Report
May 08, 2025 10-Q Quarterly Report
May 08, 2025 8-K Current Report
Apr 21, 2025 4 Filing
Apr 21, 2025 4 Filing